



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/572,740

12/04/2006

Robert Hofmeister

028622-0148

5289

22428 7590 09/22/2010
FOLEY AND LARDNER LLP
SUITE 500
3000 K STREET NW
WASHINGTON, DC 20007

EXAMINER

GUSSOW, ANNE

ART UNIT

PAPER NUMBER

1643

MAIL DATE

DELIVERY MODE

09/22/2010

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/572,740	Applicant(s) HOFMEISTER ET AL.	
	Examiner ANNE M. GUSSOW	Art Unit 1643	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 18 May 2010.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-7,9,13,15-17,19-35 and 37-41 is/are pending in the application.
- 4a) Of the above claim(s) 27-31 is/are withdrawn from consideration.
- 5) ☒ Claim(s) 1-7,9,13,15-17,19,21,23,25,32-35 and 41 is/are allowed.
- 6) ☒ Claim(s) 20,22,24,26 and 37 is/are rejected.
- 7) ☒ Claim(s) 38-40 is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date <u>7/15/10</u> . | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

1. Claims 1 and 37 have been amended.

Claims 8, 10-12, 14, 18, and 36 have been cancelled.

Claims 27-31 remain withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on November 20, 2009.

Applicant's arguments filed May 18, 2010 regarding withdrawn claims 20, 22, 24, and 26 have been carefully considered by the examiner and will be examined to the extent that the claims read on the elected species of SEQ ID Nos. 88, 92, 96, 100, 102, and 104.

2. Claims 1-7, 9, 13, 15-17, 19-26, 32-35, and 37-41 are under examination.
3. The following office action contains NEW GROUNDS of Rejection.

Information Disclosure Statement

4. The information disclosure statement (IDS) submitted on July 15, 2010 was filed after the mailing date of the first action on the merits on February 19, 2010. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the

Art Unit: 1643

information disclosure statement has been considered by the examiner and an initialed copy of the IDS is included with the mailing of this office action.

Objections Withdrawn

5. The objection to the abstract is withdrawn in view of applicant's amendment to the abstract.
6. The objections to the specification are withdrawn in view of applicant's amendment to the specification and arguments regarding the sequences.

Rejections Withdrawn

7. The rejection of claims 1-19, 21, 23, 25, 32-35, and 37-41 under 35 U.S.C. 112, second paragraph as being indefinite is withdrawn in view of applicant's amendment to the claims.
8. The rejection of claim 18 under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement is withdrawn in view of applicant's cancellation of the claim.
9. The rejection of claims 1-19, 21, 23, 25, 32-35, and 37-41 under 35 U.S.C. 112, first paragraph, as lacking enablement is withdrawn in view of applicant's amendment to the claims.
10. The rejection of claims 37-40 under 35 U.S.C. 112, first paragraph, as lacking enablement is withdrawn in view of applicant's amendment to the claims.

Art Unit: 1643

11. The rejection of claims 1-13, 15, 16, and 33 under 35 U.S.C. 101 as being drawn to a non-statutory subject matter is withdrawn in view of arguments and amendment to the claims to require the second binding domain to be an scFv.

12. The rejection of claims 1, 3, 5, 15-17, 32-35, and 37-40 under 35 U.S.C. 103(a) as being obvious over Bendig, et al. in view of Joliffe, et al. is withdrawn in view of applicant's arguments.

13. The rejection of claims under 35 U.S.C. 103(a) as being obvious over Joliffe, et al. in view of Carr, et al. is withdrawn in view of applicant's arguments.

Rejections Maintained/NEW GROUNDS of Rejection

14. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

15. Claim 37 recites the limitation "in need of such a prevention" in the last line of the claim. There is insufficient antecedent basis for this limitation in the claim.

16. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

17. Claims 20, 22, 24, and 26 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably

Art Unit: 1643

convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The claims are drawn to isolated amino acids, amino acids encoded by a nucleic acid sequence, amino acid sequences encoded by degenerate nucleic acid sequences, or amino acid sequences encoded by nucleic acid hybridizing under stringent conditions to a nucleotide sequence complementary to a nucleic acid sequence.

The specification discloses antibodies encoded by specific amino acid sequences encoded by specific nucleic acid sequences.

The specification does not provide sufficient written description as to the structural features of the claimed genus of nucleic acids and encoded polypeptides and the correlation between the chemical structure and function of the genus of nucleic acids, such as structural domains or motifs that are essential and distinguish members of the genus from those excluded. The nucleic acids that hybridize to the complement of SEQ ID No. 30, for example (although the rejection applies to each of the SEQ ID Nos. in claimed part a) would comprise a large range of diversity because molecules which hybridize would not specifically bind to each and every residue of a sequence. Thus, one of ordinary skill in the art would not know the structure of the hybridizing nucleic acids that would be associated with the binding activity.

A "representative number of species" means that the species, which are adequately described are representative of the entire genus. Thus, when there is substantial variation within the genus, one must describe a sufficient variety of species to reflect the variation within the genus. The disclosure of only one species

Art Unit: 1643

encompassed within a genus adequately describes a claim directed to that genus only if the disclosure "indicates that the patentee has invented species sufficient to constitute the gen[us]." See *Enzo Biochem*, 323 F.3d at 966, 63 USPQ2d at 1615; *Noelle v. Lederman*, 355 F.3d 1343, 1350, 69 USPQ2d 1508, 1514 (Fed. Cir. 2004) (Fed. Cir. 2004)("[A] patentee of a biotechnological invention cannot necessarily claim a genus after only describing a limited number of species because there may be unpredictability in the results obtained from species other than those specifically enumerated."). "A patentee will not be deemed to have invented species sufficient to constitute the genus by virtue of having disclosed a single species when ... the evidence indicates ordinary artisans could not predict the operability in the invention of any species other than the one disclosed." In re *Curtis*, 354 F.3d 1347, 1358, 69 USPQ2d 1274, 1282 (Fed. Cir. 2004)(Claims directed to PTFE dental floss with a friction-enhancing coating were not supported by a disclosure of a microcrystalline wax coating where there was no evidence in the disclosure or anywhere else in the record showing applicant conveyed that any other coating was suitable for a PTFE dental floss.).

It has been well known that minor structural differences even among structurally related compounds can result in substantially different biology, expression and activities. Based on the instant disclosure one of skill in the art would not know which sequences are essential, which sequences are non-essential and what particular sequence lengths identify essential sequences for identifying a nucleic acid encompassed by the claimed specificity. For example, there is insufficient guidance based on the reliance of disclosure of SEQ ID No. 30 to direct a person of skill in the art

Art Unit: 1643

to select or to predict particular sequences as essential for identifying nucleic acids encompassed by the claimed specificities. Mere idea of function is insufficient for written description; isolation and characterization at a minimum are required.

Skolnick et al (Trends in Biotechnology, 2000. Vol. 18, pages 34-39) teach that the skilled artisan is well aware that assigning functional activities for any particular protein or protein family based on sequence homology is inaccurate, in part because of the multifunctional nature of proteins (e.g., “Abstract” and “Sequence-based approaches to function prediction”, page 34). Even in situations where there is some confidence of a similar overall structure between two proteins, only experimental research can confirm the artisan’s best guess as to function of the structurally related protein (see in particular “Abstract” and Box 2).

Protein chemistry is probably one of the most unpredictable areas of biotechnology. For example, the replacement of a single lysine at position 118 of the acidic fibroblast growth factor by a glutamic acid led to a substantial loss of heparin binding, receptor binding, and biological activity of the protein (see Burgess et al, Journal of Cell Biology, 1990. Vol 111, pages 2129-2138). In transforming growth factor alpha, replacement of aspartic acid at position 47 with asparagine, did not affect biological activity while the replacement with serine or glutamic acid sharply reduced the biological activity of the mitogen (see Lazar, et al. Molecular and Cellular Biology, 1988. Vol 8, pages 1247-1252).

In the absence of sufficient guidance and direction to the structural and functional analysis, applicant’s reliance on the binding of the polypeptide encoded by SEQ ID No.

Art Unit: 1643

30 disclosed in the specification as-filed does not appear to provide sufficient written description for the genus of nucleic acids encompassed by the claimed specificities in view of the above evidence, which indicates ordinary artisans could not predict the operability in the invention of any species other than the one disclosed.

For inventions in an unpredictable art, adequate written description of a genus, which embraces widely variant species cannot be achieved by disclosing only one species within the genus. In the instant case, applicant has not even disclosed a single species encompassed by the highly variant genus nor is there disclosure of the common attributes or features (i.e., structural domains) that are essential for activity or those which are non-essential. See, e.g., *Eli Lilly*. Description of a representative number of species does not require the description to be of such specificity that it would provide individual support for each species that the genus embraces. If a representative number of adequately described species are not disclosed for a genus, the claim to that genus must be rejected as lacking adequate written description under 35 U.S.C. 112, first paragraph.

Vas-Cath Inc. v. Mahurkar, 19USPQ2d 1111, clearly states “applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession *of the invention*. The invention is, for purposes of the ‘written description’ inquiry, *whatever is now claimed*.” (See page 1117.) The specification does not “clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed.” (See *Vas-Cath* at page 1116). As discussed above, the skilled artisan cannot envision the detailed chemical structure of the

Art Unit: 1643

encompassed genus of polypeptides, and therefore conception is not achieved until reduction to practice has occurred, regardless of the complexity or simplicity of the method of isolation. Adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method of isolating it. The compound itself is required. See *Fiers v. Revel*, 25 USPQ2d 1601 at 1606 (CAFC 1993) and *Amgen Inc. v. Chugai Pharmaceutical Co. Ltd.*, 18 USPQ2d 1016.

One cannot describe what one has not conceived. See *Fiddles v. Baird*, 30 USPQ2d 1481, 1483. In *Fiddles v. Baird*, claims directed to mammalian FGF's were found unpatentable due to lack of written description for the broad class. The specification provided only the bovine sequence.

Therefore, only isolated nucleic acids comprising the SEQ ID Nos. in part b and nucleic acids encoding the amino acid SEQ ID Nos. in part a of the claims, but not the full breadth of the claim meets the written description provision of 35 U.S.C. § 112, first paragraph. Applicant is reminded that Vas-Cath makes clear that the written description provision of 35 U.S.C. § 112 is severable from its enablement provision (see page 1115).

Conclusion

18. Claims 1-7, 9, 13, 15-17, 19, 21, 23, 25, 32-35, and 41 appear to be in condition for allowance.

Claims 20, 22, 24, 26, and 37 are rejected.

Claims 38-40 are objected to as being dependent upon a rejected base claim.

19. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ANNE M. GUSSOW whose telephone number is (571)272-6047. The examiner can normally be reached on Monday - Friday 8:30 am - 5 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Misook Yu can be reached on (571) 272-0839. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Anne M. Gussow
September 20, 2010

/Anne M. Gussow/
Examiner, Art Unit 1643